Breaking News Instant updates and real-time market news.

CTSH

Cognizant

$53.25

1.39 (2.68%)

13:08
11/28/16
11/28
13:08
11/28/16
13:08

Cognizant small dividend seems achievable, says SunTrust

After Elliott Management disclosed a $1.4B position and released a letter to Cognizant Technology Solutions, SunTrust analyst Frank Atkins says he believes the company's major issue is not on the margin side but declining top line growth rates. A small dividend, as Elliott suggested, seems achievable and may fit with slightly lower top line trajectory going forward, Atkins tells investors in a research note. He continues to believe a Trump administration creates uncertainty and keeps a Hold rating on shares of Cognizant.

  • 28

    Nov

CTSH Cognizant
$53.25

1.39 (2.68%)

10/31/16
KEYB
10/31/16
NO CHANGE
KEYB
Cognizant should report upbeat earnings, says KeyBanc
KeyBanc says that Cognizant can increase investor confidence by "clarifying the impact from potential FCPA violations and President Gordon Coburn's abrupt departure." The firm thinks that the company's negative comments and lowered guidance are priced into the stock at current levels. It believes that the set-up for the company heading into its Q3 results is positive. The firm reiterates a $67 price target and an Overweight rating on the shares.
11/22/16
BOFA
11/22/16
DOWNGRADE
BOFA
Underperform
Cognizant downgraded two notches to Underperform at BofA/Merrill
BofA/Merrill analyst David Ridley-Lane downgraded Cognizant two notches to Underperform from Buy and lowered its price target to $48 from $66. The analyst sees risks from potential immigration reform under a Trump administration and a slower growth profile. Further, Ridley-Lane said revenue growth at Cognizant's largest customers has stalled and views a reacceleration of growth in 2017 as unlikely.
11/23/16
WBLR
11/23/16
DOWNGRADE
WBLR
Market Perform
Cognizant downgraded to Market Perform from Outperform at William Blair
William Blair analyst Anil Doradla downgraded Cognizant Technology Solutions to Market Perform.
11/23/16
WBLR
11/23/16
DOWNGRADE
WBLR
Market Perform
Cognizant downgraded to Market Perform from Outperform at William Blair
William Blair analyst Anil Doradla downgraded Cognizant Technology Solutions to Market Perform from Outperform. After visiting India, the analyst is concerned that Cognizant will be affected by structural changes within the services industry. The newest headwind to the industry is related to the potential policy changes under President-elect Trump, Doradla tells investors in a research note. Further, the analyst is disappointed by the company's lack of capital returns to shareholders. He also expects Cognizant's growth will continue decelerating from 2016 through 2018. In pre-market trading, the shares are down 53c to $52.65.

TODAY'S FREE FLY STORIES

SBUX

Starbucks

$57.21

-1.3 (-2.22%)

17:09
12/04/16
12/04
17:09
12/04/16
17:09
Conference/Events
Starbucks to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

CS

Credit Suisse

$13.39

-0.34 (-2.48%)

17:03
12/04/16
12/04
17:03
12/04/16
17:03
Conference/Events
Credit Suisse to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 14

    Dec

TKPYY

Takeda Pharmaceutical Co. Ltd.

$20.40

0.135 (0.67%)

, SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

17:02
12/04/16
12/04
17:02
12/04/16
17:02
Hot Stocks
Takeda Pharma, Seattle Genetics reports Phase 3 ADCETRIS data »

Takeda Pharmaceutical…

TKPYY

Takeda Pharmaceutical Co. Ltd.

$20.40

0.135 (0.67%)

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

CGEN

Compugen

$5.95

0.1 (1.71%)

16:59
12/04/16
12/04
16:59
12/04/16
16:59
Conference/Events
Compugen to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

QURE

uniQure

$5.68

-0.31 (-5.18%)

16:56
12/04/16
12/04
16:56
12/04/16
16:56
Hot Stocks
uniQure reports data on AMT-060 in hemophilia B »

uniQure announced new and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 08

    Dec

RGLS

Regulus

$2.50

0.1 (4.17%)

16:53
12/04/16
12/04
16:53
12/04/16
16:53
Conference/Events
Regulus to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 14

    Dec

PBI

Pitney Bowes

$14.63

0.1 (0.69%)

16:52
12/04/16
12/04
16:52
12/04/16
16:52
Conference/Events
Pitney Bowes to host analyst day »

Analyst Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

16:43
12/04/16
12/04
16:43
12/04/16
16:43
Hot Stocks
Seattle Genetics reports Phase 1b vadastuximab talirine data, plans Ph. 2 trial »

Seattle Genetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

NVS

Novartis

$68.17

0.42 (0.62%)

16:38
12/04/16
12/04
16:38
12/04/16
16:38
Hot Stocks
Novartis reports Phase 2 SEG101 data »

Novartis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

PFE

Pfizer

$31.63

0.17 (0.54%)

16:33
12/04/16
12/04
16:33
12/04/16
16:33
Hot Stocks
Pfizer reports Phase 2 glasdegib data »

Pfizer announced new data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

EKSO

Ekso Bionics

$4.27

-0.11 (-2.51%)

16:30
12/04/16
12/04
16:30
12/04/16
16:30
Conference/Events
Ekso Bionics to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

ADSK

Autodesk

$70.57

1.35 (1.95%)

16:24
12/04/16
12/04
16:24
12/04/16
16:24
Conference/Events
Autodesk to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

  • 09

    Jan

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

16:23
12/04/16
12/04
16:23
12/04/16
16:23
Hot Stocks
Seattle Genetics reports Phase 2 ADCETRIS lymphoma data, says discontinues trial »

Seattle Genetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

FTI

FMC Technologies

$35.60

0.9 (2.59%)

, TKPPY

Technip

$17.80

0.45 (2.59%)

16:21
12/04/16
12/04
16:21
12/04/16
16:21
Conference/Events
Technip to host special shareholder meeting »

Special Shareholder…

FTI

FMC Technologies

$35.60

0.9 (2.59%)

TKPPY

Technip

$17.80

0.45 (2.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

TKPPY

Technip

$17.80

0.45 (2.59%)

, FTI

FMC Technologies

$35.60

0.9 (2.59%)

16:14
12/04/16
12/04
16:14
12/04/16
16:14
Conference/Events
FMC Technologies to host special shareholder meeting »

Special Shareholder…

TKPPY

Technip

$17.80

0.45 (2.59%)

FTI

FMC Technologies

$35.60

0.9 (2.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

16:04
12/04/16
12/04
16:04
12/04/16
16:04
Hot Stocks
Alnylam reports interim Phase 1 data on fitusiran »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADRO

Aduro Biotech

$10.80

0.25 (2.37%)

16:01
12/04/16
12/04
16:01
12/04/16
16:01
Hot Stocks
Aduro Biotech reports presentation of BION-1301 data »

Aduro Biotech announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRIL

Trillium Therapeutics

$6.70

-0.5 (-6.94%)

15:59
12/04/16
12/04
15:59
12/04/16
15:59
Hot Stocks
Trillium Therapeutics reports presentation of TTI-621 data »

Trillium Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

BLUE

bluebird bio

$69.75

1.1 (1.60%)

15:47
12/04/16
12/04
15:47
12/04/16
15:47
Hot Stocks
bluebird bio reports new data from HGB-205 study of LentiGlobin »

bluebird bio announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLCM

Bellicum Pharmaceuticals

$18.72

1.74 (10.25%)

15:43
12/04/16
12/04
15:43
12/04/16
15:43
Hot Stocks
Bellicum Pharmaceuticals reports updated data from BPX-501 study »

Bellicum Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

15:39
12/04/16
12/04
15:39
12/04/16
15:39
Hot Stocks
Alnylam reports Phase 1 givosiran data, says plans Phase 3 study late 2017 »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$31.63

0.17 (0.54%)

, ONCE

Spark Therapeutics

$50.01

0.27 (0.54%)

15:32
12/04/16
12/04
15:32
12/04/16
15:32
Hot Stocks
Spark Therapeutics, Pfizer report updated preliminary data on SPK-9001 »

Spark Therapeutics (ONCE)…

PFE

Pfizer

$31.63

0.17 (0.54%)

ONCE

Spark Therapeutics

$50.01

0.27 (0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 04

    Dec

  • 06

    Dec

  • 06

    Dec

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

15:26
12/04/16
12/04
15:26
12/04/16
15:26
Conference/Events
Seattle Genetics to hold an investor reception »

Management reviews the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$27.20

-0.1 (-0.37%)

15:21
12/04/16
12/04
15:21
12/04/16
15:21
Conference/Events
Roche to hold an analyst meeting »

Analyst Meeting to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

15:17
12/04/16
12/04
15:17
12/04/16
15:17
Hot Stocks
Juno Therapeutics reports Phase 1 data on JCAR014 »

Juno Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.